Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Patents show all

40Applications7Issued

Clinical Trials show all

1Phase 11Phase 2

SEC Filings show all

D3

SEC Form D Funding Events

DateOfferedSoldType
2010-11-08$2,500,000$2,500,000Debt, Option to Acquire, Security to be Acquired
2010-06-18$1,200,000$1,200,000Debt, Option to Acquire, Security to be Acquired
2008-08-06UnknownUnknownOther (Paper Filing)

Key Executives

  • Philip J. Vickers
    Executive Officer, Director
  • James Nichols
    Executive Officer
  • Per Gjorstrup
    Executive Officer
  • C. Eric Schwartz
    Executive Officer
  • Timothy J. Barberich
    Director
  • Douglas Cole
    Director
  • Jean-francois Formela
    Director
  • Keith Manchester
    Director
  • George M. Milne, Jr.
    Director
  • Gregory Weinhoff
    Director